Skip to content

Omniox

3 viewers · 30d

Total raised

$24.1M

1 filing since 2016 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $24.1M
ROUNDS
1
INVESTORS
93
FOUNDED
N/A
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Omniox, Inc. is a San Francisco biotherapeutics company developing engineered protein oxygen carriers for diseases driven by tissue hypoxia. Its H-NOX platform technology produces OMX biologics designed to deliver oxygen selectively into pathologically hypoxic tissue, where low oxygen drives disease progression and worsens outcomes. The lead candidate, OMX-4.80P, is a PEGylated H-NOX oxygen carrier developed to reduce tumor hypoxia and sensitize glioblastoma and other solid tumors to radiotherapy. Founded in 2006, the company is at the investigational new drug (IND) stage, with published preclinical results in intracranial glioblastoma models and a phase 0 trial in canine brain cancer.

What sets it apart

The engineered H-NOX scaffold binds oxygen with tuned affinity so it offloads only into severely hypoxic tissue rather than throughout the circulation, and the PEGylated form extends circulating half-life from roughly 1 hour to 30-35 hours with tumor accumulation out to 48 hours while remaining non-immunogenic in preclinical testing.

Funding history

1 round
DebtAug 1, 2016
Form D
+$24.1M$24.1M total

Latest SEC filings

via EDGAR · CIK 0001553710
Form D · Aug 1, 2016View on EDGAR

Products

1 tracked

OMX-4.80P

Biologic therapeutic (protein oxygen carrier)

A PEGylated engineered H-NOX protein oxygen carrier that penetrates and oxygenates hypoxic tumors, developed to enhance the efficacy of radiotherapy in glioblastoma and other hypoxic solid tumors.

  • Engineered H-NOX protein scaffold that releases oxygen into severely hypoxic tissue
  • PEGylation extends circulating half-life to roughly 30-35 hours and tumor accumulation to about 48 hours
  • Non-immunogenic in preclinical testing
  • Downregulates the HIF-1 pathway and increases tumor response to radiation therapy

Links

WebsiteLinkedInSEC EDGAR filings